A Randomized Trial of 5-Hydroxytryptamine4-Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation

Andrea Shin, Andres Acosta, Michael Camilleri, Amy Boldingh, Duane Burton, Michael Ryks, Deborah Rhoten, Alan R. Zinsmeister

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Background and Aims: YKP10811, a selective agonist of the serotonin 5-hydroxytryptamine-4 receptor, increases gastrointestinal (GI) motility. We investigated the safety and effects of YKP10811 on GI and colonic transit and bowel movements (BMs) in patients with functional constipation in a randomized, double-blind, placebo-controlled study. Methods: Patients with functional constipation, based on the Rome III criteria, were assigned randomly to groups given YKP10811 10 mg (n= 15), 20 mg (n= 16), 30 mg (n= 15), or placebo (n= 11) daily for 8 days. Transit of solids was measured by validated scintigraphy at baseline and on days 7 to 9. Patients kept diaries on days 1 to 9, recording time to first BM, number of BMs/day, and stool consistency (based on the Bristol Stool Form Scale). To evaluate safety, we collected data on adverse events and clinical laboratory test and electrocardiograms results. The primary efficacy end points were determined from an intent-to-treat analysis assessing colonic transit at 24 hours and the half-time (t1/2) of gastric emptying, using analysis of covariance models. Secondary efficacy end points included measures of colonic transit (geometric center at 4 and 24 hours), small-bowel transit (based on colon filling at 6 hours), t1/2 of ascending colon emptying, and bowel functions. We used the Dunnett test to compare the effects of each dose with placebo. A per-protocol analysis (PPA) assessed the t1/2 of gastric emptying and time to first BM using proportional hazards models. Results: Fifty-five participants completed the study. YKP10811 was associated with a significant acceleration in colon filling at 6 hours (P < .05), t1/2 of ascending colon emptying, and colonic transit at 24 and 48 hours, as well as increased stool consistency over 8 days (based on intent-to-treat analysis). In general, the 10-mg and 20-mg doses were the most effective in accelerating colonic transit. No serious adverse events were observed. Conclusions: YKP10811, a selective agonist of the serotonin receptor 5-hydroxytryptamine-4, accelerates GI and colonic transit and improves bowel functions in patients with functional constipation, compared with placebo. ClinicalTrial.Gov: NCT01523184.

Original languageEnglish (US)
Pages (from-to)701-708
Number of pages8
JournalClinical Gastroenterology and Hepatology
Volume13
Issue number4
DOIs
StatePublished - Apr 1 2015
Externally publishedYes

Fingerprint

Constipation
Placebos
Receptors, Serotonin, 5-HT4
Gastrointestinal Transit
Ascending Colon
Gastric Emptying
Colon
Safety
Serotonin Receptor Agonists
Gastrointestinal Motility
Proportional Hazards Models
Radionuclide Imaging
Electrocardiography
carbamic acid 3-(4-((4-amino-5-chloro-2-methoxybenzoylamino)methyl)piperidin-1-yl)-1-(4-fluorophenyl)propyl ester

Keywords

  • Benzamide
  • Clinical Trial
  • Drug
  • Prokinetic

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

A Randomized Trial of 5-Hydroxytryptamine4-Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. / Shin, Andrea; Acosta, Andres; Camilleri, Michael; Boldingh, Amy; Burton, Duane; Ryks, Michael; Rhoten, Deborah; Zinsmeister, Alan R.

In: Clinical Gastroenterology and Hepatology, Vol. 13, No. 4, 01.04.2015, p. 701-708.

Research output: Contribution to journalArticle

Shin, Andrea ; Acosta, Andres ; Camilleri, Michael ; Boldingh, Amy ; Burton, Duane ; Ryks, Michael ; Rhoten, Deborah ; Zinsmeister, Alan R. / A Randomized Trial of 5-Hydroxytryptamine4-Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation. In: Clinical Gastroenterology and Hepatology. 2015 ; Vol. 13, No. 4. pp. 701-708.
@article{737837ca0d7f4ab6b9ae1c716287e388,
title = "A Randomized Trial of 5-Hydroxytryptamine4-Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation",
abstract = "Background and Aims: YKP10811, a selective agonist of the serotonin 5-hydroxytryptamine-4 receptor, increases gastrointestinal (GI) motility. We investigated the safety and effects of YKP10811 on GI and colonic transit and bowel movements (BMs) in patients with functional constipation in a randomized, double-blind, placebo-controlled study. Methods: Patients with functional constipation, based on the Rome III criteria, were assigned randomly to groups given YKP10811 10 mg (n= 15), 20 mg (n= 16), 30 mg (n= 15), or placebo (n= 11) daily for 8 days. Transit of solids was measured by validated scintigraphy at baseline and on days 7 to 9. Patients kept diaries on days 1 to 9, recording time to first BM, number of BMs/day, and stool consistency (based on the Bristol Stool Form Scale). To evaluate safety, we collected data on adverse events and clinical laboratory test and electrocardiograms results. The primary efficacy end points were determined from an intent-to-treat analysis assessing colonic transit at 24 hours and the half-time (t1/2) of gastric emptying, using analysis of covariance models. Secondary efficacy end points included measures of colonic transit (geometric center at 4 and 24 hours), small-bowel transit (based on colon filling at 6 hours), t1/2 of ascending colon emptying, and bowel functions. We used the Dunnett test to compare the effects of each dose with placebo. A per-protocol analysis (PPA) assessed the t1/2 of gastric emptying and time to first BM using proportional hazards models. Results: Fifty-five participants completed the study. YKP10811 was associated with a significant acceleration in colon filling at 6 hours (P < .05), t1/2 of ascending colon emptying, and colonic transit at 24 and 48 hours, as well as increased stool consistency over 8 days (based on intent-to-treat analysis). In general, the 10-mg and 20-mg doses were the most effective in accelerating colonic transit. No serious adverse events were observed. Conclusions: YKP10811, a selective agonist of the serotonin receptor 5-hydroxytryptamine-4, accelerates GI and colonic transit and improves bowel functions in patients with functional constipation, compared with placebo. ClinicalTrial.Gov: NCT01523184.",
keywords = "Benzamide, Clinical Trial, Drug, Prokinetic",
author = "Andrea Shin and Andres Acosta and Michael Camilleri and Amy Boldingh and Duane Burton and Michael Ryks and Deborah Rhoten and Zinsmeister, {Alan R.}",
year = "2015",
month = "4",
day = "1",
doi = "10.1016/j.cgh.2014.08.012",
language = "English (US)",
volume = "13",
pages = "701--708",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - A Randomized Trial of 5-Hydroxytryptamine4-Receptor Agonist, YKP10811, on Colonic Transit and Bowel Function in Functional Constipation

AU - Shin, Andrea

AU - Acosta, Andres

AU - Camilleri, Michael

AU - Boldingh, Amy

AU - Burton, Duane

AU - Ryks, Michael

AU - Rhoten, Deborah

AU - Zinsmeister, Alan R.

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Background and Aims: YKP10811, a selective agonist of the serotonin 5-hydroxytryptamine-4 receptor, increases gastrointestinal (GI) motility. We investigated the safety and effects of YKP10811 on GI and colonic transit and bowel movements (BMs) in patients with functional constipation in a randomized, double-blind, placebo-controlled study. Methods: Patients with functional constipation, based on the Rome III criteria, were assigned randomly to groups given YKP10811 10 mg (n= 15), 20 mg (n= 16), 30 mg (n= 15), or placebo (n= 11) daily for 8 days. Transit of solids was measured by validated scintigraphy at baseline and on days 7 to 9. Patients kept diaries on days 1 to 9, recording time to first BM, number of BMs/day, and stool consistency (based on the Bristol Stool Form Scale). To evaluate safety, we collected data on adverse events and clinical laboratory test and electrocardiograms results. The primary efficacy end points were determined from an intent-to-treat analysis assessing colonic transit at 24 hours and the half-time (t1/2) of gastric emptying, using analysis of covariance models. Secondary efficacy end points included measures of colonic transit (geometric center at 4 and 24 hours), small-bowel transit (based on colon filling at 6 hours), t1/2 of ascending colon emptying, and bowel functions. We used the Dunnett test to compare the effects of each dose with placebo. A per-protocol analysis (PPA) assessed the t1/2 of gastric emptying and time to first BM using proportional hazards models. Results: Fifty-five participants completed the study. YKP10811 was associated with a significant acceleration in colon filling at 6 hours (P < .05), t1/2 of ascending colon emptying, and colonic transit at 24 and 48 hours, as well as increased stool consistency over 8 days (based on intent-to-treat analysis). In general, the 10-mg and 20-mg doses were the most effective in accelerating colonic transit. No serious adverse events were observed. Conclusions: YKP10811, a selective agonist of the serotonin receptor 5-hydroxytryptamine-4, accelerates GI and colonic transit and improves bowel functions in patients with functional constipation, compared with placebo. ClinicalTrial.Gov: NCT01523184.

AB - Background and Aims: YKP10811, a selective agonist of the serotonin 5-hydroxytryptamine-4 receptor, increases gastrointestinal (GI) motility. We investigated the safety and effects of YKP10811 on GI and colonic transit and bowel movements (BMs) in patients with functional constipation in a randomized, double-blind, placebo-controlled study. Methods: Patients with functional constipation, based on the Rome III criteria, were assigned randomly to groups given YKP10811 10 mg (n= 15), 20 mg (n= 16), 30 mg (n= 15), or placebo (n= 11) daily for 8 days. Transit of solids was measured by validated scintigraphy at baseline and on days 7 to 9. Patients kept diaries on days 1 to 9, recording time to first BM, number of BMs/day, and stool consistency (based on the Bristol Stool Form Scale). To evaluate safety, we collected data on adverse events and clinical laboratory test and electrocardiograms results. The primary efficacy end points were determined from an intent-to-treat analysis assessing colonic transit at 24 hours and the half-time (t1/2) of gastric emptying, using analysis of covariance models. Secondary efficacy end points included measures of colonic transit (geometric center at 4 and 24 hours), small-bowel transit (based on colon filling at 6 hours), t1/2 of ascending colon emptying, and bowel functions. We used the Dunnett test to compare the effects of each dose with placebo. A per-protocol analysis (PPA) assessed the t1/2 of gastric emptying and time to first BM using proportional hazards models. Results: Fifty-five participants completed the study. YKP10811 was associated with a significant acceleration in colon filling at 6 hours (P < .05), t1/2 of ascending colon emptying, and colonic transit at 24 and 48 hours, as well as increased stool consistency over 8 days (based on intent-to-treat analysis). In general, the 10-mg and 20-mg doses were the most effective in accelerating colonic transit. No serious adverse events were observed. Conclusions: YKP10811, a selective agonist of the serotonin receptor 5-hydroxytryptamine-4, accelerates GI and colonic transit and improves bowel functions in patients with functional constipation, compared with placebo. ClinicalTrial.Gov: NCT01523184.

KW - Benzamide

KW - Clinical Trial

KW - Drug

KW - Prokinetic

UR - http://www.scopus.com/inward/record.url?scp=84925161998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925161998&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2014.08.012

DO - 10.1016/j.cgh.2014.08.012

M3 - Article

VL - 13

SP - 701

EP - 708

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 4

ER -